BusinessMelinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United StatesBy Nasdaq OMXJan 29, 2018, 12:00 PM UTC
BusinessMelinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines CompanyBy Nasdaq OMXNov 29, 2017, 12:00 PM UTC
BusinessMelinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United StatesBy Nasdaq OMXOct 30, 2017, 12:01 PM UTC
BusinessMelinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging ComorbiditiesBy Nasdaq OMXOct 24, 2017, 12:01 PM UTC
BusinessMelinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeekBy Nasdaq OMXOct 4, 2017, 5:14 PM UTC
BusinessMelinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other InfectionsBy Nasdaq OMXSep 25, 2017, 12:01 PM UTC
BusinessMelinta Therapeutics Presentations at ECCMID Show Potential of Baxdela in Obese and other Challenging Patient TypesBy Nasdaq OMXApr 21, 2017, 1:37 PM UTC
BusinessMelinta Therapeutics Highlighting Activity of Baxdela as well as Progress on Macrolide and Pyrrolocytosine Candidates at ECCMID 2017By Nasdaq OMXApr 19, 2017, 6:43 PM UTC
